drugset / Trial / NCT07275645

A Clinical Trial of Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried in a Population Aged 10 to 60 Years

NCT07275645 ↗

Phase 3 Active not recruiting 3000 enrolled Ab&B Bio-tech Co., Ltd.JS
RandomizedParallel-groupDouble-blindPrevention

Summary

A total of 3,000 participants will be enrolled, stratified by age into two groups: 600 participants aged 10-17 years and 2,400 participants aged 18-60 years. Within each age group, participants will be randomly assigned in a 1:1:1:1:1 ratio to one of five vaccination schedule groups: Essen Control Group (Group A), Essen Experimental Group (Group B), Zagreb Experimental Group (Group C), Simplified Four-Dose Group 1 (Group D), and Simplified Four-Dose Group 2 (Group E). Among participants in the four experimental groups-Essen Experimental Group, Zagreb Experimental Group, Simplified Four-Dose Group 1, and Simplified Four-Dose Group 2-stratified block randomization will be applied. Within each age group and each vaccination schedule group, participants will be further randomized in a 1:1:1 ratio into three subgroups: those receiving a booster dose at Day 90 after completion of the primary immunization, those receiving a booster dose at Day 180, and those undergoing assessment of immune persistence at Day 360 after completion of the primary immunization.

Timeline

Start
2026-02-26
Primary completion
2026-04-26
Completion
2027-04-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rabies Vaccine(Human Diploid Cell)for Human Use,Freeze-dried Vaccine 1 ml Intramuscular

Indications